Nov 15, 2016 Cellectar Biosciences Announces INC Research as the CRO for the Phase II Trial of CLR 131 in Hematologic Malignancies; $2M NCI Grant Covers Half of Study Cost, with Potential Option to Pursue Additional $3M for Pivotal Trial Learn More
Nov 11, 2016 UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results Learn More
Nov 10, 2016 Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results Learn More
Nov 7, 2016 Cellectar Biosciences to Host Conference Call on November 11 to Report Third Quarter 2016 Financial Results and Corporate Performance Learn More